NCT00890500View on ClinicalTrials.gov

Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

May 31, 2013

Study Completion Date

October 31, 2013

Conditions
Hematologic MalignanciesAllogeneic Stem Cell Transplantation
Interventions
DRUG

Fludarabine

30mg/m2/day IV x 6 days

DRUG

Melphalan

100 mg/m2/day IV x 1 day

DRUG

Antithymocyte Globulin

1mg/kg/day x 4 days

DRUG

Sirolimus

GVHD Prophylaxis: Target range 3-12 ng/ml

DRUG

Tacrolimus

GVHD Prophylaxis: Target range 5-10 ng/ml

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

Sponsors

Lead Sponsor

Fate Therapeutics
All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

lead

Fate Therapeutics

INDUSTRY

NCT00890500 - Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies. | Biotech Hunter | Biotech Hunter